|

Phase 1a: LB-LR1109 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • LG Chem1

Indications

  • Renal Cell Carcinoma (RCC)1
  • Malignant Melanoma1
  • Head and Neck Squamous Cell Carcinoma (HNSCC)1
  • Urothelial Carcinoma1
  • Non-small Cell Lung Cancer (NSCLC)1

Fairfax, Virginia1 trial

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

NEXT Oncology

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.